MYOK - マイオカ―ディア (MyoKardia Inc.)

MYOKのニュース

   MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020  2020/07/28 12:00:00 GlobeNewswire
BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and…
   Hypertrophic Cardiomyopathy Pipeline 2020 Featuring Algomedix, Celltrion, MyoKardia, Novartis and 4 Others - ResearchAndMarkets.com  2020/07/27 14:18:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Hypertrophic Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypertrophic Cardiomyopathy is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline's potential. Development of Hypertrophic Cardiomyopathy medicines is identified as integral to the strateg
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO  2020/05/15 11:49:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) Allogene Therapeutics Inc (NASDAQ: ALLO )(reacted to ASCO abstract ) Altimmune Inc (NASDAQ: ALT )(announced first-quarter results and update to its COVID-19 vaccine program) BioXcel Therapeutics Inc (NASDAQ: BTAI )( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) Co-Diagnostics Inc (NASDAQ: CODX ) Myokardia Inc (NASDAQ: MYOK ) Repligen Corporation (NASDAQ: RGEN ) Translate Bio Inc (NASDAQ: TBIO ) VBI Vaccines Inc (NASDAQ: VBIV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) Genfit SA (NASDAQ: GNFT ) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) RA Medical Systems Inc (NYSE: RMED )(reacted to first-quarter results) Recro Pharma Inc (NASDAQ: REPH ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN Stocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ: NK ) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   MyoKardia (MYOK) Joins $100 Stock Price Club  2020/05/12 06:27:00 RTT News
Shares of MyoKardia Inc. (MYOK) touched an all-time high of $104.26 in intraday trading on Monday, before closing at $96.90, thanks to positive top-line data from the Company's phase III EXPLORER study of Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy.
   Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit  2020/05/11 14:59:21 24/7 Wall street
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   MyoKardia (MYOK) Joins $100 Stock Price Club  2020/05/12 06:27:00 RTT News
Shares of MyoKardia Inc. (MYOK) touched an all-time high of $104.26 in intraday trading on Monday, before closing at $96.90, thanks to positive top-line data from the Company's phase III EXPLORER study of Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy.
   Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit  2020/05/11 14:59:21 24/7 Wall street
   MyoKardia Reports First Quarter 2020 Financial Results  2020/05/06 20:05:00 GlobeNewswire
BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31,…
   The 9 top biotech stocks to buy now to get through the coronavirus crisis, according to JPMorgan  2020/04/03 15:57:00 Business Insider
In an April 3 research note, JPMorgan identified nine biotechnology companies they see as the best investment ideas for 2020. In past recessions, in 2001 and 2008-2009, the biotech industry outperformed the broader market. This time around, JPMorgan sees smaller biotechs facing a few big risks, such as disruptions to clinical trials and tightening liquidity for the capital markets. Here are the bank's top ideas of 2020 in the biotech industry. Visit Business Insider's homepage for more stories . As the coronavirus pandemic roils financial markets, JPMorgan analysts are highlighting the biotechnolgy industry as one space that has outperformed in past recessions. In 2008-2009, a leading biotech index outperformed by gaining 1% while the broader market dropped 23%. And in the 2001 recession, the analysts state that same biotech index held flat while the S&P 500 dropped 9%. This time around, biotech does face some heightened risks. Small companies that depend on clinical trials running on time and launching new drugs could face setbacks , because of the coronavirus overwhelming the healthcare system.

calendar